Non-compliance occurs particularly in patients with chronic illness and with variable symptoms over time, as in asthma. Non-compliance in asthma might contribute to its morbidity (1) . In order to prevent poor compliance and prescribe effectively, physicians should take into account treatment factors that contribute to poor compliance.
The breath-actuate d inhaler (Autohaler) is a device that is triggered by the inspiratory air ow produced by the patient. It is easier to use than the metered dose inhaler (MDI), because patients are not dependent on hand -lung coordination, which could in uence compliance. We therefore studied the effect of the inhalation device (Autohaler and MDI) on medication compliance in asthmatic patients and determined the in uence on compliance of patients' subjective opinion about both devices.
Patients with chronic air ow obstruction often use different drugs in combination with regimen requiring multiple daily dosage during a long period. It is known that a prescribed frequent daily use results in poor compliance (2, 3) . We investigated the compliance rates with different daily frequency by means of an Autohaler, which we expected to show a more positive effect on compliance compared with the MDI. We also investigated the effect of duration of treatment on the degree of compliance.
MATERIAL AND METHODS

Patients
Asthmatic patients were recruited from a research project investigating the effect of bronchodilator treatment on air ow sensitivity in a placebo-controlled design (4) . Patients used three inhalers daily, two Autohalers and one MDI, over a period of 12 weeks. One Autohaler had to be used twice daily, the other four times daily. The MDI had to be used twice daily. Extensive instruction on how to use the different devices was given by a lung function technician before the start of the trial. The trial was approved by the Ethics Committee of the University of Nijmegen and informed consent was obtained from each patient.
Assessment of medication compliance
Medication was weighed before and after use in order to assess the amount used. Devices were collected without prior announcement (5) and new ones delivered 6 weeks after the start of the trial during a regular visit to the homes of patients. Furthermore, medication was collected when the patient visited the laboratory at the end of the study period. Medication compliance rates were expressed as: medication used as a percentage of medication prescribed. Power A clinically relevant difference of 12.5% in medication compliance (1, 5) can be detected with an a of 0.05 and a b of 0.20 and a standard deviation of 25% with a sample size of at least 34 subjects.
Patients' opinions towards the inhalation device
RESULTS
Patients
The total number of patients meeting the inclusion criteria was 34, which was suf cient for the power needed. Their mean age was 37 (SD 13) years, 19 were women, PC 20 (geometric mean) was 0.92 mg histamine: ml (95% CI 0.48 -1.75), FEV 1 % of predicted was 80% (SD 18).
Medication compliance
The median value of the compliance rate of the total amount of medication used, expressed as a percentage of the prescribed medication, was 87.1% (25-75th percentile 61.8% -94.6%). In 65% of the patients, compliance rates were between 80% and 120%. Underuse (less than 80% of the prescribed dose) was far more common than overuse (above 120% of the prescribed dose), in 34% and 1.0% of the patients, respectively.
Effect of device, daily frequency and treatment period
There was no effect of device on medication compliance (p ¾ 0.317). The median values for the compliance rate of the MDI and the Autohaler (with twice daily frequency) were 95.7% (25-75th percentile 83.9 -99.9%) and 90.8% (25-75th percentile 61.6-98.0%), respectively. The median values for the compliance rate of the Autohaler with twice and four times daily frequency were 90.8% (25-75th percentile 61.6 -98.0%) and 78.5% (25-75th percentile 49.0-91.2%), respectively, and differed signi cantly (p ¾ 0.001). There was a signi cant effect of treatment period on medication compliance in the Autohaler that had to be used four times daily (p ¾ 0.05). The median compliance percentage of the Autohaler (four times daily) was 79.6% (25-75th percentile 54.8 -90.8%) in the rst 6 weeks of the trial and 75.6% (25-75th percentile 48.4 -90.7%) in the second half of the study period.
Patients' opinions towards the MDI and the autohaler
The numbers of patients who evaluated their device as inconvenient, neutral and convenient are presented in Fig. 1 . The mean compliance percentage in patients with a negative opinion towards the MDI and the Autohaler was 83% (SD ¾30%) and 61% (SD ¾ 39%), respectively. In patients with a positive opinion towards the MDI and the Autohaler, compliance rates were 77% (SD ¾ 38%) and 74% (SD ¾35%), respectively.
DISCUSSION
The results of the present study show that there was no difference in compliance between the two different inhalation devices (MDI and Autohaler). This contrasts with our expectation that patients would be more compliant with use of the Autohaler than with use of the MDI. A possible explanation could be that the Autohaler is a relatively new device compared with the MDI, and some patients might be relatively unfamiliar with it. There were more patients who disliked the MDI than there were patients who found the Autohaler inconvenient. Opinions about the devices, however, did not seem to have an in uence on medication compliance. A corresponding conclusion has been found by Arshad et al. (6) , who reported that no signi cant Fig. 1 . Patients' subjective opinions concerning the inhalation device (n ¾ 34, MDI ¾ metered dose inhaler) ( ¾inconvenient; ¾ neutral; ¾ convenient).
difference was identi ed between the Autohaler and the MDI in respect of bronchodilator usage.
In this study, we observed that the most important factor for compliance was the relatively highly prescribed frequency of four times daily. It has been reported earlier that compliance is reduced when daily dosage is doubled (2) . Therefore, when the impact of compliance is included in determining medication treatment, a low daily frequency is obviously preferable to a high daily frequency. This is relevant for medical care when we compare, for instance, short-acting with long-acting bronchodilators. In conclusion, the devices (MDI and Autohaler) and patients' opinions about the devices did not signi cantly contribute to the compliance rates. Compliance towards medication treatment, however, is negatively in uenced by high daily frequency.
